Who is sponsoring NCT00791479?

NCT00791479 is sponsored by Eli Lilly and Company.

What condition does NCT00791479 study?

NCT00791479 studies Diabetes Mellitus, Type 2.

What drugs are being tested in NCT00791479?

Interventions: LY2189265 and Lifestyle Measures, Placebo solution and Lifestyle Measures.

What is the status of NCT00791479?

NCT00791479 is currently COMPLETED.

Last reviewed 2014-12-08 · How we verify

Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions

NCT00791479 Phase 2 COMPLETED Results posted

This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 2
Status	COMPLETED
Enrolment	167
Start date	2008-12
Completion	2010-01

Conditions

Diabetes Mellitus, Type 2

Interventions

LY2189265 and Lifestyle Measures
Placebo solution and Lifestyle Measures

Primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) — Baseline, 12 weeks
Least Squares (LS) means of change from baseline for glycosylated hemoglobin (HbA1c) were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HbA1c as covariate.

Countries

United States, Croatia, Denmark, India, Mexico, Poland, Puerto Rico, Russia, Spain